Ultrasound therapy provider Theraclion said it has received 900,000 euros as a refundable advance to develop new applications of high-intensity focused ultrasound (HIFU) in noninvasive treatments for benign tumor ablation.
The grant came from Bpifrance's "Industrial Strategic Innovation" program established to promote French companies.
Representing stage 5 of the so-called TUCE project underway in collaboration with SuperSonic Imagine, the new grant funding recognizes the success of the projects earlier stages of TUCE, which aims to develop a medical system that can ablate benign tumors such as breast fibroadenomas and thyroid nodules without need of invasive treatments, according to Theraclion.
The TUCE project, established in 2009, uses HIFU technology guided by SuperSonic Imagine's imaging technology, which also analyzes changes in the treated tissue, Theraclion said. It uses HIFU guided by SuperSonic Imagine's innovative imaging technology, and also monitors changes in treated tissue.
